Damar_2017_Med.Hypotheses_99_57

Reference

Title : Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease - Damar_2017_Med.Hypotheses_99_57
Author(s) : Damar U , Gersner R , Johnstone JT , Schachter S , Rotenberg A
Ref : Med Hypotheses , 99 :57 , 2017
Abstract :

Alzheimer's disease (AD) is the most frequent cause of dementia. Besides cognitive deterioration, patients with AD are prone to seizures - more than 20% of patients diagnosed with AD experience at least one unprovoked seizure and up to 7% have recurrent seizures. Although available antiepileptic drugs (AEDs) may suppress seizures in patients with AD, they may also worsen cognitive dysfunction and increase the risk of falls. On the basis of preclinical studies, we hypothesize that Huperzine A (HupA), a safe and potent acetylcholinesterase (AChE) inhibitor with potentially disease-modifying qualities in AD, may have a realistic role as an anticonvulsant in AD.

PubMedSearch : Damar_2017_Med.Hypotheses_99_57
PubMedID: 28110700

Related information

Citations formats

Damar U, Gersner R, Johnstone JT, Schachter S, Rotenberg A (2017)
Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease
Med Hypotheses 99 :57

Damar U, Gersner R, Johnstone JT, Schachter S, Rotenberg A (2017)
Med Hypotheses 99 :57